{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
histamine
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at human (pKi=9.24) H3 receptor and was developed by Johnson & Johnson Pharmaceutical. During preclinical studies were shown that JNJ-5207852 might be useful in the treatment of cognitive impairment in epilepsy. On animal models was discovered, that this compound readily penetrates the brain tissue after subcutaneous administration.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
JNJ-10181457 is a histamine H3 receptor antagonist, which was developed by Johnson & Johnson. Selective blockade of histamine H3 receptors might have therapeutic utility for the treatment of working memory deficits and learning disorders, especially those in which ACh neurotransmission is compromised.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dimaprit (S-[3-(N,N-dimethylamino)propyl]isothiourea) has been shown to be a highly specific histamine H2-receptor agonist.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
SKF-91488 is a noncompetitive inhibitor of histamine-N-methyltransferase. It modulates the effects of exogenous histamine and endogenously released histamine induced by antigen challenge on plasma extravasation in the airway in guinea pigs in vivo. SKF-91488 raised dose-dependently the pain threshold in rodent antinociception tests. Endogenous central histamine, after SKF 91488 treatment, via activation of H, receptors produces reversal of hypotension, with improvement in the survival rate at 2 h after treatment, in rats subjected to critical haemorrhagic hypovolaemia.
